The 2016 Advanced Clinical Educator Program in Multiple Myeloma: A CE-Certified Serial Learning Approach to Bridging Communication and Educational Gaps in MM

This activity includes:

  • Module I: Multiple Myeloma Disease Overview and Diagnostic Workup
  • Module II: Treatment of Multiple Myeloma in the First-Line, Maintenance, and Relapsed/Refractory Settings
  • Module III: Survivorship and Side Effect Management in Patients With Multiple Myeloma

Purpose
The Multiple Myeloma Advanced Clinical Educator (ACE) Program provides tools and resources that will enable oncology/hematology nurses to gain expertise and competence by applying new skills in multiple myeloma clinical practice with the support and guidance of a more specialized and experienced multiple myeloma advisor/clinical expert.

Course Overview
The AXIS Medical Education ACE Program in MM provides a focused, interactive, peer-to-peer educational experience for 20 ACE candidates, leading to ACE status. The objective of the program is not only to improve ACE candidates’ knowledge, competency, and level of performance in the treatment and management of MM, but also to build their skills as subject matter experts and speakers in this therapeutic area.

These self-study activities were completed by ACE candidates enrolled in the ACE program and are now available to oncology nurses who were unable to participate in the ACE program. AXIS will compare the gains achieved within the activities by the ACE candidates with those learners participating outside of the program to demonstrate the value in improving knowledge, confidence, competence, performance, and retention by participating in the ACE program.

Target Audience

This activity is designed for oncology/hematology nurses who treat or manage multiple myeloma.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

Module I: Multiple Myeloma Disease Overview and Diagnostic Workup
     •    Explain the pathophysiology of multiple myeloma
     •    Assess the diagnostic workup of patients with multiple myeloma
     •    Describe the various methods of staging multiple myeloma
Module II: Treatment of Multiple Myeloma in the First-Line, Maintenance, and Relapsed/Refractory Settings
     •    Assess the latest data on the safety and efficacy of current and emerging treatment options in the newly diagnosed, maintenance, and relapsed/refractory disease settings
     •    Describe education strategies to help patients understand their treatment options
     •    Develop an evidence-based nursing care plan for patients with multiple myeloma based on disease- and treatment-related symptoms
Module III: Survivorship and Side Effect Management in Patients With Multiple Myeloma
     •    Describe effective nursing management of common adverse events, including skeletal-related events, peripheral neuropathy, and deep venous thrombosis
     •    Identify how to help patients cope with long-term survivorship issues
     •    Develop education strategies to help patients understand how to recognize and manage side effects

Activity Agenda

Module I: Multiple Myeloma Disease Overview and Diagnostic Workup

Module II: Treatment of Multiple Myeloma in the First-Line, Maintenance, and Relapsed/Refractory Settings

Module III: Survivorship and Side Effect Management in Patients With Multiple Myeloma

Course summary
Course opens: 
09/08/2016
Course expires: 
09/07/2017
Cost:
$0.00
Rating: 
0

Co- Chairs

Beth Faiman, PhD, RN, APRN-BC, AOCN®
Adult Nurse Practitioner
Cleveland Clinic Taussig Cancer Institute
Adjunct Faculty
Case Western University
Cleveland, Ohio
Ursuline College
Pepper Pike, Ohio
Kent State University
Kent, Ohio

 

Sandra E. Kurtin, MS, RN, ANP-C, AOCN®
Nurse Practitioner
Clinical Assistant Professor of Medicine
Adjunct Clinical Assistant Professor of Nursing
The University of Arizona Cancer Center
Tucson


Nursing Continuing Education 
Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.

This educational activity for 1.0 contact hour for each module is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information 
For information about the accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com 

Instructions to Receive Credit
To receive credit for these activities, the participant must read the learning objectives and faculty disclosures and study the educational activities.  

Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.

Disclosure of Conflicts of Interest 
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or PresenterReported Financial Relationship

Beth Faiman, PhD, RN, APRN-BC, AOCN®

Consultant/Independent contractor: Celgene Corporation; Millennium Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.; Speakers' bureau: Celgene Corporation; Millennium Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.

Sandra E. Kurtin, MS, RN, ANP-C, AOCN®

Consultant/Independent contractor: Bristol-Myers Squibb Company; Celgene Corporation; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Honoraria: Bristol-Myers Squibb Company; Celgene Corporation; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited.


The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or ManagerReported Financial Relationship
Ashley Marostica, RN, MSN Nothing to disclose
Amanda Glazar, PhDNothing to disclose
Andrea FunkNothing to disclose
Laura Gilsdorf    Nothing to disclose
Linda Gracie-King, MS    Nothing to disclose
Ronald Viggiani, MD    Nothing to disclose

Isabelle Vacher

Nothing to disclose
Jocelyn Timko, BSNothing to disclose

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and AXIS Medical Education do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This activity is supported by educational grants provided by Celgene Corporation, Novartis Pharmaceuticals, and Takeda Oncology.

There is no fee for this educational activity.

This activity is provided by

AXIS 1390

Available Credit

Accreditation Period

Course opens: 
09/08/2016
Course expires: 
09/07/2017

Price

Cost:
$0.00
Please login or register to take this course.